First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis.

Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase 3 studies of adjunctive brivaracetam treatment

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. 

Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase 3 studies

Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase 3 studies

Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies

Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus

Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures

Observed incidence rates of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. 

Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy